In This Article:
-
Total Revenue (Q4 2024): SEK553 million, a growth of 48% year-over-year.
-
Product Sales (Q4 2024): SEK469 million, up 28% year-over-year and 11% quarter-over-quarter.
-
Brixadi Royalty Income (Q4 2024): SEK83 million, a 43% increase from the previous quarter.
-
Total Revenue (Full Year 2024): SEK1,868 million, a 9% increase year-over-year.
-
Earnings Per Share (2024): SEK7.20, with a profit after tax of SEK429 million.
-
Cash Position (End of 2024): SEK2.85 billion, improved by SEK101 million during the quarter.
-
Gross Margin (Q4 2024): 94%, an improvement of 267 basis points year-over-year.
-
Total OPEX (Q4 2024): SEK357 million, a 4% decrease year-over-year.
-
R&D Investment (Full Year 2024): SEK684 million, 37% of total revenue.
-
Profit Before Taxes (Q4 2024): SEK186 million, an increase of SEK204 million from Q4 2023.
-
Profit Before Taxes (Full Year 2024): SEK553 million, a 286% increase excluding one-time impacts.
-
Buvidal Sales (Q4 2024): SEK469 million, up 11% quarter-over-quarter and 28% year-over-year.
-
Buvidal Sales (Full Year 2024): SEK1.65 billion, a 27% increase year-over-year.
-
Brixadi Market Share (15 months post-launch): Approximately 25% of the long-acting segment.
-
2025 Revenue Guidance: SEK2.7 billion to SEK3 billion, representing a growth of 45% to 61%.
-
2025 Profit Before Tax Guidance: SEK0.9 billion to SEK1.2 billion, an increase of 63% to 117%.
Release Date: February 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Camurus AB (FRA:7CA) achieved a total revenue of SEK553 million in Q4 2024, marking a 48% growth compared to the same period last year.
-
The company reported a strong gross margin of 94% for the quarter, an improvement of 267 basis points from the previous year.
-
Buvidal sales showed significant growth, with a 28% increase year-over-year and an 11% increase from the previous quarter.
-
Camurus successfully established a fully operational US commercial organization, preparing for the launch of Oakla in Acromegaly.
-
The company maintained a strong cash position, ending the quarter with SEK2.85 billion and no debt.
Negative Points
-
Camurus received a complete response letter from the FDA due to issues at a third-party manufacturing facility, delaying the approval process for CAM2029 in the US.
-
The company faced a temporary setback in the US regulatory review process, impacting the timeline for CAM2029's market entry.
-
Operating expenses reached SEK357 million, representing a 4% decrease, but still indicating significant investment requirements.
-
The estimated time for reaching the target of 194 events for the Soreto trial's primary results was updated to late 2025 or early 2026, indicating potential delays.
-
The company incurred one-time expenses of SEK8 million related to a potential transaction, impacting the financial results.